Around 75% of breast tumours express estrogen receptor (ER+). Endocrine therapy (ET) is a cornerstone in the treatment of both early and metastatic disease, but its effectiveness is limited by the developing of acquired resistance and more rarely by de novo resistance. Understanding the mechanisms of resistance to ET represents a challenge. Recently acquired mutations in ESR1, have been associated with resistance to aromatase inhibitor (Ai) therapy in hormone-refractory metastatic breast cancer (MBC).
Estrogen receptor mutation: a new strategy to overcome endocrine resistance
Moretti, A
Primo
;Lupini, L;Carandina, I;Bassi, C;Lancia, F;Daniel, F;Belluomini, L;Toma, I;Bannò, E;Nisi, C;Da Ros, L;Querzoli, P;Negrini, MPenultimo
;Frassoldati, AUltimo
2017
Abstract
Around 75% of breast tumours express estrogen receptor (ER+). Endocrine therapy (ET) is a cornerstone in the treatment of both early and metastatic disease, but its effectiveness is limited by the developing of acquired resistance and more rarely by de novo resistance. Understanding the mechanisms of resistance to ET represents a challenge. Recently acquired mutations in ESR1, have been associated with resistance to aromatase inhibitor (Ai) therapy in hormone-refractory metastatic breast cancer (MBC).File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
2017_abstract Annals of oncology.pdf
accesso aperto
Tipologia:
Full text (versione editoriale)
Licenza:
PUBBLICO - Pubblico con Copyright
Dimensione
69.69 kB
Formato
Adobe PDF
|
69.69 kB | Adobe PDF | Visualizza/Apri |
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
